Differential effects of the CCKA receptor ligands PD-140,548 and A-71623 on latent inhibition in the rat.
Latent inhibition (LI) is a behavioural paradigm in which repeated exposure to a stimulus without consequence inhibits the formation of any new associations with that stimulus. To the extent that LI reflects a process of leaming to ignore irrelevant stimuli, disrupted LI has been suggested as an animal model for the attentional deficits observed in schizophrenia. The antipsychotic potential of cholecystokinin (CCK) stems from its colocalization with dopamine (DA) in the mesolimbic pathway, where it demonstrates both excitatory and inhibitory effects on dopaminergic activity. This may be explained by mediation through different receptor subtypes. A variety of hypotheses has emerged regarding the potential clinical application of subtype-selective CCK-based drugs. The present experiments examined the effects on LI of two selective CCK(A) ligands: PD-140,548 (a CCK(A) antagonist, Experiment 1: 0.001, 0.01, and 0.1 mg/kg) and A-71623 (a CCK(A) agonist, Experiment 2: 0.02, 0.05, and 0.1 mg/kg). In both experiments, the effects of haloperidol (0.1 mg/kg) were also investigated. Animals receiving 0.1 mg/kg of haloperidol or 0.001 or 0.1 mg/kg (but not 0.01 mg/kg) of PD-140,548 treated the preexposed stimulus as irrelevant after a low number of preexposures. In contrast, no facilitatory effect on LI was detectable at any of the A-71623 doses. The finding that A-71623 failed to enhance LI indicates that it is unlikely that this compound would have any antipsychotic effect within the clinical setting. Considering the facilitatory effect exerted by PD-140,548 on LI, it is probable that the inhibition of CCK activity might prove a more promising strategy for the pharmacological treatment of schizophrenia.
Gracey
David J
DJ
Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Northern Ireland, UK.
Bell
Robert
R
King
David J
DJ
D000818:Animals; D006220:Haloperidol / Q000494:pharmacology; D007211:Indoles / Q000378:metabolism / Q000494:pharmacology*; D007266:Inhibition, Psychological; D008024:Ligands; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology; D013758:Tetragastrin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*
D007211:Indoles; D008024:Ligands; C102662:PD 140548; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D013758:Tetragastrin; C066278:A 71623; D006220:Haloperidol